M. Rizzo

Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.

P. Narciso, A. Antinori, A. De Luca, 2003, The Journal of infectious diseases.

Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.

G. Ippolito, A. Antinori, V. Tozzi, 2001, AIDS.

Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals

A. De Luca, A. Cingolani, B. Ciancio, 2002, Neurology.

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)

A. Antinori, A. De Luca, A. Cingolani, 2002, AIDS.

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.

Andrea De Luca, P. Narciso, A. Antinori, 2002, AIDS research and human retroviruses.

Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.

C. Perno, A. De Luca, A. Cingolani, 2001, AIDS.

Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.

A. Vandamme, G. Zissis, K. Van Laethem, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.